Study Details

Diabetics and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring—Hyper K

Douglas Roblin, David H. Smith, Co-Investigators


This study determines the incidence of hyperkalemia-associated adverse outcomes among ambulatory patients with diabetes newly initiating angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers, and/or aldosterone receptor antagonists and to explore whether an association exists between monitoring serum potassium and hyperkalemia-associated adverse outcomes.
Funding source: National Institute of Diabetes & Digestive & Kidney Diseases

Our Locations
Three Regions — One Mission
Each CHR site conducts professionally independent, public domain research and disseminates its findings in the scholarly literature and scientific community.

Northwest
 3800 N. Interstate
Portland, OR 97227      
503.335.2400

Hawaii
 711 Kapiolani Blvd.
Suite 200
Honolulu, HI 96813
101.222.2400 		Southeast
 3495 Piedmont Road, NE
Ten Piedmont Center,
Suite 205
Atlanta, GA 30305
202.555.1212

US Map

 
Kaiser Permanente